Search Results - "Papageorgiou, Sokratis"

Refine Results
  1. 1

    Current and Future Treatments in Alzheimer Disease: An Update by Yiannopoulou, Konstantina G, Papageorgiou, Sokratis G

    “…Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive research. Nowadays, only symptomatic treatments exist for this…”
    Get full text
    Book Review Journal Article
  2. 2

    Current and future treatments for Alzheimer’s disease by Yiannopoulou, Konstantina G., Papageorgiou, Sokratis G.

    “…Alzheimer’s dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and…”
    Get full text
    Book Review Journal Article
  3. 3

    APOE Genotype and Alzheimer’s Disease: The Influence of Lifestyle and Environmental Factors by Angelopoulou, Efthalia, Paudel, Yam Nath, Papageorgiou, Sokratis G, Piperi, Christina

    Published in ACS chemical neuroscience (04-08-2021)
    “…Alzheimer’s disease (AD) is the most common neurodegenerative disorder with obscure pathogenesis and no disease-modifying therapy to date. AD is multifactorial…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7

    Emerging Therapeutic Potential of Fluoxetine on Cognitive Decline in Alzheimer's Disease: Systematic Review by Bougea, Anastasia, Angelopoulou, Efthalia, Vasilopoulos, Efthimios, Gourzis, Philippos, Papageorgiou, Sokratis

    “…Fluoxetine, a commonly prescribed medication for depression, has been studied in Alzheimer's disease (AD) patients for its effectiveness on cognitive symptoms…”
    Get full text
    Journal Article
  8. 8

    Exploring the Genetic Landscape of Mild Behavioral Impairment as an Early Marker of Cognitive Decline: An Updated Review Focusing on Alzheimer's Disease by Angelopoulou, Efthalia, Koros, Christos, Hatzimanolis, Alexandros, Stefanis, Leonidas, Scarmeas, Nikolaos, Papageorgiou, Sokratis G

    “…The clinical features and pathophysiology of neuropsychiatric symptoms (NPSs) in dementia have been extensively studied. However, the genetic architecture and…”
    Get full text
    Journal Article
  9. 9

    Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson's Disease by Angelopoulou, Efthalia, Bougea, Anastasia, Paudel, Yam Nath, Georgakopoulou, Vasiliki Epameinondas, Papageorgiou, Sokratis G, Piperi, Christina

    Published in Medicina (Kaunas, Lithuania) (01-06-2023)
    “…: Parkinson's disease (PD) is a clinically heterogeneous disorder with poorly understood pathological contributing factors. Depression presents one of the most…”
    Get full text
    Journal Article
  10. 10

    Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson's Disease Pathogenesis: A Narrative Review by Angelopoulou, Efthalia, Paudel, Yam Nath, Papageorgiou, Sokratis G, Piperi, Christina

    Published in Brain sciences (28-01-2022)
    “…Parkinson's disease (PD) is the second most common neurodegenerative disorder with an unclear etiology and no disease-modifying treatment to date. PD is…”
    Get full text
    Journal Article
  11. 11

    Episodic Memory in Alzheimer Disease, Frontotemporal Dementia, and Dementia With Lewy Bodies/Parkinson Disease Dementia: Disentangling Retrieval From Consolidation by Economou, Alexandra, Routsis, Christopher, Papageorgiou, Sokratis G

    Published in Alzheimer disease and associated disorders (01-01-2016)
    “…Differences in episodic memory performance in patients with Alzheimer disease (AD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB)/Parkinson…”
    Get full text
    Journal Article
  12. 12
  13. 13

    A case of corticobasal syndrome possibly associated with anti-Yo antibodies by Angelopoulou, Efthalia, Constantinides, Vasilios C, Koumasopoulos, Evangelos, Stanitsa, Evangelia, Pyrgelis, Efstratios-Stylianos, Kyrozis, Andreas, Kapaki, Elisabeth, Stefanis, Leonidas, Papageorgiou, Sokratis G

    Published in Current medical research and opinion (02-10-2024)
    “…Corticobasal syndrome (CBS) is a rare form of atypical parkinsonism, most commonly caused by neurodegenerative disorders. Autoimmune underlying conditions are…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Structural and functional impairment of the retina and optic nerve in Alzheimer's disease by Moschos, Marilita M, Markopoulos, Ioannis, Chatziralli, Irini, Rouvas, Alexandros, Papageorgiou, Sokratis G, Ladas, Ioannis, Vassilopoulos, Dimitrios

    Published in Current Alzheimer research (01-09-2012)
    “…The purpose of this study was to evaluate the macular and retinal nerve fiber layer (RNFL) thickness, and the electrical activity of the macula in patients…”
    Get more information
    Journal Article
  16. 16

    Psychosis in Parkinson’s Disease: A Lesson from Genetics by Angelopoulou, Efthalia, Bougea, Anastasia, Papageorgiou, Sokratis G, Villa, Chiara

    Published in Genes (20-06-2022)
    “…Psychosis in Parkinson’s disease (PDP) represents a common and debilitating condition that complicates Parkinson’s disease (PD), mainly in the later stages…”
    Get full text
    Journal Article
  17. 17

    Physical Training In-Game Metrics for Cognitive Assessment: Evidence from Extended Trials with the Fitforall Exergaming Platform by Konstantinidis, Evdokimos I., Bamidis, Panagiotis D., Billis, Antonis, Kartsidis, Panagiotis, Petsani, Despoina, Papageorgiou, Sokratis G.

    Published in Sensors (Basel, Switzerland) (26-08-2021)
    “…Conventional clinical cognitive assessment has its limitations, as evidenced by the environmental shortcomings of various neuropsychological tests conducted…”
    Get full text
    Journal Article
  18. 18

    The nonverbal BriefScreen: A cognitive screening method for patients with limited language and motor abilities by Economou, Alexandra, Varlokosta, Spyridoula, Kontari, Panagiota, Papageorgiou, Sokratis G.

    Published in Applied neuropsychology. Adult (04-03-2023)
    “…Dementia and significant cognitive decline are frequent sequelae of stroke, but are difficult to evaluate when aphasia and/or motor impairment are present. The…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Elucidating the Beneficial Effects of Ginger (Zingiber officinale Roscoe) in Parkinson’s Disease by Angelopoulou, Efthalia, Paudel, Yam Nath, Papageorgiou, Sokratis G., Piperi, Christina

    Published in ACS pharmacology & translational science (14-10-2022)
    “…Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease (AD), and its pathogenesis remains obscure. Current…”
    Get full text
    Journal Article